Anvisa meets Embrapa's request and authorizes research on Cannabis cultivation by the institution

The Collegiate Board of the National Health Surveillance Agency (Anvisa) approved, this Wednesday (11/19), an exceptional authorization for Embrapa to conduct research on the cultivation of the Cannabis sativa plant.

Before starting the studies, Embrapa will undergo an on-site inspection by Anvisa and must comply with a series of requirements to ensure safety and material control. The authorization will be monitored by the Agency, which may request additional adjustments.

No product resulting from the research may be commercialized. Embrapa may only send plant material not suitable for propagation to other duly authorized research institutions.

Why is this important?

According to the rapporteur of the process, the director of the Fifth Board of Anvisa, Thiago Lopes Cardoso Campos, the authorization reinforces the Agency's commitment to science, innovation, and health security.

“It is science that should guide the country. This authorization allows Brazil to produce its own knowledge, strengthen its technological autonomy, and fulfill its duty to public health and national development,” he said.

The director also emphasized that research focused on real challenges of the country is essential to generate its own technology, reduce external dependencies, and increase Brazil's ability to compete globally.

Check here the full rapporteur's vote.

What will Embrapa research?

The authorization allows the company to develop three main lines of study:

• Conservation and characterization of germplasm (Embrapa Genetic Resources and Biotechnology)

• Germplasm is the plant's genetic material, essential for studies and genetic improvement.

• Scientific and technological bases for medicinal cannabis

• (Embrapa Temperate Climate)

• Pre-breeding of hemp for fibers and seeds

• (Embrapa Cotton)

Embrapa justified the request citing the growing global interest in Cannabis, which today has economic, social, environmental, and medicinal importance. The company also reaffirmed its readiness to comply with all technical and safety requirements defined by Anvisa.

 Source: Anvisa